Peginterferon Alfa-2a (HBV, HCV)Other Names: PEG-interferon alfa-2a (HBV, HCV), Pegasys (HBV, HCV), pegIFN alfa-2a (HBV, HCV), pegylated-interferon alfa 2a (HBV, HCV) Drug Class: Opportunistic Infections and Coinfections
What is peginterferon alfa-2a?
Peginterferon alfa-2a is anprescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic and chronic . HBV and HCV infections are HIV-related . An opportunistic infection is an infection that occurs more frequently or is more severe in people with weakened immune systems—such as those infected with HIV—than in people with healthy immune systems.
The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the
In addition to recommendations for the medicine’s use in treating chronic HBV and HCV infections, the guidelines and the guidance include recommendations on the “off-label” use of peginterferon alfa-2a to treat acute HCV infection in HIV-infected individuals. “Off-label” use refers to use of an FDA-approved medicine in a manner different from that described on the medicine label. Good medical practice and the best interests of a patient sometimes require that a medicine be used “off-label.”
What should I tell my health care provider before taking peginterferon alfa-2a?
Before taking peginterferon alfa-2a, tell your health care provider:
- If you are allergic to peginterferon alfa-2a or any other medicines.
- About any medical conditions you have or have had, for example, or problems.
- About anything that could affect your ability to take medicines, such as missing a scheduled or any health conditions that may prevent your use of medicines.
- If you are pregnant or plan to become pregnant. You may take peginterferon alfa-2a with another medicine called ribavirin. Ribavirin may cause birth defects or death of an unborn child. Pregnant women and men whose partners are pregnant should not use ribavirin. Talk to your health care provider about possible risks with taking peginterferon alfa-2a when pregnant.
- If you are breastfeeding or plan to breastfeed. Do not breastfeed if you are infected with HIV.
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Peginterferon alfa-2a may affect the way other medicines or products work, and other medicines or products may affect how peginterferon alfa-2a works. Ask your health care provider if there are interactions between peginterferon alfa-2a and the other medicines you take.
Ask your health care provider about possible side effects from peginterferon alfa-2a. Your health care provider will tell you what to do if you have side effects.
How should I take peginterferon alfa-2a?
Take peginterferon alfa-2a according to your health care provider’s instructions. Your health care provider will tell you how much peginterferon alfa-2a to take and when to take it. Before you start peginterferon alfa-2a and each time you get a refill, read any printed information that comes with your medicine.
How should peginterferon alfa-2a be stored?
- Store peginterferon alfa-2a single use vials, prefilled syringes, and autoinjectors in the refrigerator, between 36°F and 46°F (2°C to 8°C). Do not leave peginterferon alfa-2a out of the refrigerator for more than 24 hours.
- Do not freeze or shake peginterferon alfa-2a.
- Protect peginterferon alfa-2a from light.
- Vials, prefilled syringes, and autoinjectors are for single use only. Discard any unused portion remaining in the vial or prefilled syringe.
- Throw away peginterferon alfa-2a that is no longer needed or expired (out of date). Follow FDA guidelines on how to safely dispose of unused medicine.
- Keep peginterferon alfa-2a and all medicines out of reach of children.
Where can I find more information about peginterferon alfa-2a?
More information about peginterferon alfa-2a is available:
- Recommendations on the HIV-related uses of peginterferon alfa-2a, from the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by CDC, NIH, and IDSA-HIVMA.
- Recommendations on the HIV-related uses of peginterferon alfa-2a, from the Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus, prepared by AASLD, IDSA, and IAS-USA.
- Peginterferon alfa-2a-related research studies, from the AIDSinfo database of study summaries.
The above Patient Version drug summary is based on the following FDA label(s): Injection (solution), kit.
Last Reviewed: May 19, 2016